Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
12 Articles
12 Articles
Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company focused on developing innovative therapies and technologies, today announced that it has entered into a Study […]
The Toronto Star
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company focused on developing innovative therapies and technologies, today announced that it has entered into a Study Start-Up Agreement (“SUA”) with the…
New therapy moves closer to Phase 2 testing in progressive MS
Quantum Biopharma is collaborating with Thermo Fisher Scientific to prepare a Phase 2 clinical trial of Lucid-MS, an experimental oral therapy designed to slow myelin loss, in people with progressive forms of multiple sclerosis (MS). Under the agreement, Thermo Fisher’s PPD clinical research business will support Quantum with study start-up activities and related clinical research […]
Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
New agreement moves innovative Lucid-MS treatment from planning into execution. Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. Thermo Fisher’s clinical research business is a leading global contract research organization, with impressive expertise in central nervous system and MS studies. LOS ANGELES, CA - October 7, 2026 (NEWMEDIAWIRE) - Most m…
Quantum BioPharma Advances Multiple Sclerosis Trial with Thermo Fisher Partnership
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific to launch a Phase 2 trial of Lucid-MS for progressive multiple sclerosis, marking a critical step in developing a first-in-class neuroprotective therapy. The post Quantum BioPharma Advances Multiple Sclerosis Trial with Thermo Fisher Partnership appeared first on citybuzz.
Coverage Details
Bias Distribution
- 86% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
